CME ActivitiesJDD Webinars

Actinic Keratosis: Current Understanding of Pathophysiology and Therapeutic Targets

By April 9, 2021April 21st, 2021No Comments

JDD Multimedia

Watch on Demand

Watch Now to Earn 1.0 CE Credit! 

Claim CME

Actinic Keratosis: Current Understanding of Pathophysiology and Therapeutic Targets

Featuring Brian Berman, MD, PhD

Join JDD for Part One of this two-part webinar series on “Advancing the Understanding of Actinic Keratosis: New Treatment Options and Strategies.” In this continuing education activity, faculty will explore the pathophysiology and differential diagnosis of actinic keratosis. Dr. Berman will review understanding of therapeutic targets of AK treatment approaches.

Upon completion of this enduring, internet-based webinar, participants should be able to:

  • Review current understanding of the pathophysiology and differential diagnosis of actinic keratosis
  • Discuss therapeutic targets of actinic keratosis treatment strategies

Faculty


Brian Berman, MD, PhD
Emeritus Professor of Dermatology and Cutaneous Surgery
University of Miami Miller School of Medicine, Miami, FL
Co-Director, Center for Clinical and Cosmetic Research, Miami Beach, Florida

You May Also Like

Treating Acne in Adolescents and Young Adults

| Acne, CME Activities, JDD Webinars | No Comments
Watch Now to Earn 1.0 CE Credit!  Join Drs. Leon H. Kirick, Anthony Mancini, and Adelaide Hebert, as they  explore the categorization and grading of acne by age of onset…

Recognizing Nuances in the Diagnosis & Management of Acne in Skin of Color Patients

| Acne, CME Activities, JDD Webinars, Skin of Color | No Comments
Watch Now to Earn 1.0 CE Credit!  Join Dr. Leon H. Kircik and Andrew Alexis, MD, MPH as they discuss they nuances in the diagnosis and management of acne in…

What’s New in Topical Treatment for Actinic Keratosis

| CME Activities, JDD Webinars | No Comments
In this one-hour CME webinar, participants will learn the latest information on new topical therapeutic considerations for actinic keratosis, including the recently approved SrC kinase inhibitor. Upon completion of this…

Leave a Reply